Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical implications of ageing for the management of IBD
Christina Ha, Seymour Katz
Nature Reviews Gastroenterology & Hepatology (2013) Vol. 11, Iss. 2, pp. 128-138
Closed Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Epidemiology and Pathogenesis of Ulcerative Colitis
Lillian Du, Christina Ha
Gastroenterology Clinics of North America (2020) Vol. 49, Iss. 4, pp. 643-654
Closed Access | Times Cited: 423
Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease
Triana Lobatón, Marc Ferrante, P. Rutgeerts, et al.
Alimentary Pharmacology & Therapeutics (2015) Vol. 42, Iss. 4, pp. 441-451
Open Access | Times Cited: 170
Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease
Ashwin N. Ananthakrishnan, Hai Yun Shi, Whitney Tang, et al.
Journal of Crohn s and Colitis (2016) Vol. 10, Iss. 10, pp. 1224-1236
Open Access | Times Cited: 143
The effect of age on the intestinal mucus thickness, microbiota composition and immunity in relation to sex in mice
Marlies Elderman, Bruno Sovran, Floor Hugenholtz, et al.
PLoS ONE (2017) Vol. 12, Iss. 9, pp. e0184274-e0184274
Open Access | Times Cited: 123
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
Vijay Yajnik, Nabeel Khan, Marla C. Dubinsky, et al.
Advances in Therapy (2017) Vol. 34, Iss. 2, pp. 542-559
Open Access | Times Cited: 88
Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study
Tomer Adar, David Faleck, Saranya Sasidharan, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 49, Iss. 7, pp. 873-879
Open Access | Times Cited: 88
Aging and IBD: A New Challenge for Clinicians and Researchers
Adam S. Faye, Jean‐Frédéric Colombel
Inflammatory Bowel Diseases (2021) Vol. 28, Iss. 1, pp. 126-132
Closed Access | Times Cited: 65
Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases
Alexander S. Qian, Nghia Nguyen, Jessica Elia, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 10, pp. 2054-2063.e14
Open Access | Times Cited: 68
Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients
Michiel E. de Jong, Lisa Smits, B van Ruijven, et al.
Journal of Crohn s and Colitis (2020) Vol. 14, Iss. 7, pp. 888-895
Open Access | Times Cited: 62
Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies
Jacob J. Rozich, Parambir S. Dulai, Mathurin Fuméry, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 18, Iss. 11, pp. 2437-2447.e6
Open Access | Times Cited: 50
Is it time to include older adults in inflammatory bowel disease trials? A call for action
Sophie Vieujean, Bénédicte Caron, Vipul Jairath, et al.
The Lancet Healthy Longevity (2022) Vol. 3, Iss. 5, pp. e356-e366
Open Access | Times Cited: 35
Are neurodegenerative diseases associated with an increased risk of inflammatory bowel disease? A two-sample Mendelian randomization study
Guanghui Cui, Shaojie Li, Hui Ye, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 31
Natural History of Elderly-onset Ulcerative Colitis: Results from a Territory-wide Inflammatory Bowel Disease Registry
Hai Yun Shi, Francis K.L. Chan, Wai K. Leung, et al.
Journal of Crohn s and Colitis (2015) Vol. 10, Iss. 2, pp. 176-185
Open Access | Times Cited: 59
Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases
Ashwin N. Ananthakrishnan, Andrew Cagan, Tianrun Cai, et al.
Alimentary Pharmacology & Therapeutics (2015) Vol. 41, Iss. 11, pp. 1141-1148
Open Access | Times Cited: 45
Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric
Siddharth Singh, Sherman Picardo, Cynthia H. Seow
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 6, pp. 1367-1380
Open Access | Times Cited: 37
Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT
Siddharth Singh, Larry Stitt, Guangyong Zou, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 49, Iss. 9, pp. 1188-1194
Open Access | Times Cited: 35
Dietary Alpha‐Ketoglutarate Promotes Epithelial Metabolic Transition and Protects against DSS‐Induced Colitis
Qiyu Tian, Alejandro Bravo Iniguez, Qi Sun, et al.
Molecular Nutrition & Food Research (2021) Vol. 65, Iss. 7
Closed Access | Times Cited: 24
The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives
Ian Arnott, Gerhard Rogler, Jonas Halfvarson
Inflammatory Intestinal Diseases (2017) Vol. 2, Iss. 4, pp. 189-199
Open Access | Times Cited: 30
Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people
Matthias Butter, Stefan Weiler, Luc Biedermann, et al.
Maturitas (2018) Vol. 110, pp. 71-78
Open Access | Times Cited: 28
Elevated miR‐124‐3p in the aging colon disrupts mucus barrier and increases susceptibility to colitis by targeting T‐synthase
Li Huang, Tingyi Sun, Liang‐jun Hu, et al.
Aging Cell (2020) Vol. 19, Iss. 11
Open Access | Times Cited: 27
Microbial–Immune Crosstalk in Elderly-Onset Inflammatory Bowel Disease: Unchartered Territory
Guanmin Meng, Tanya Monaghan, Niharika A. Duggal, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 8, pp. 1309-1325
Open Access | Times Cited: 8
Benefits and Challenges of Treat-to-Target in Inflammatory Bowel Disease
Jack West, Katrina Tan, Jalpa Devi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6292-6292
Open Access | Times Cited: 8
MiR-1-3p and MiR-124-3p Synergistically Damage the Intestinal Barrier in the Ageing Colon
Tingyi Sun, Yaqi Li, Fu‐qian Zhao, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 4, pp. 656-667
Open Access | Times Cited: 18
Natural History of Crohnʼs Disease in Elderly Patients Diagnosed Over the Age of 70 Years
Mathurin Fuméry, Benjamin Pariente, Hélène Sarter, et al.
Inflammatory Bowel Diseases (2016) Vol. 22, Iss. 7, pp. 1698-1707
Open Access | Times Cited: 20
Handgrip strength and risk of malnutrition are associated with an increased risk of hospitalizations in inflammatory bowel disease patients
Katherine Bedard, Lorian Taylor, Naheed Rajabali, et al.
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top